Inventor · disambiguated record
David J. Bearss
Also filed as: BEARSS DAVID · BEARSS DAVID J · BEARSS DAVID JAMES
56 granted patents·50 pending applications·680 citations·filing 2002–2025
99Inventor score
Files withTOLERO PHARMACEUTICALS INC22HALIA THERAPEUTICS INC15SUPERGEN INC14SUMITOMO PHARMA ONCOLOGY INC10SUMITOMO DAINIPPON PHARMA ONCOLOGY INC7
Top patents by PatentIndex Score
106 records- 0197US9758539B2Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Sep 12, 2017·24 cites·13 claims
- 0296US10835537B2Combination therapies for treatment of cancerSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Granted Nov 17, 2020·7 cites·6 claims
- 0396US10568887B2Combination therapies for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Feb 25, 2020·10 cites·1 claims
- 0496US10259835B2Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2017·Granted Apr 16, 2019·17 cites·13 claims
- 0596US9901574B2Predicting response to alvocidib by mitochondrial profilingTOLERO PHARMACEUTICALS INC·Filed 2016·Granted Feb 27, 2018·18 cites·12 claims
- 0696US7750007B2Imidazo[1,2-beta]pyridazine and pyrazolo[1,5-alpha]pyrimidine derivatives and their use as protein kinase inhibitorsSUPERGEN INC·Filed 2007·Granted Jul 6, 2010·97 cites·9 claims
- 0795US11161852B1Inhibitors of NEK7 kinaseHALIA THERAPEUTICS INC·Filed 2021·Granted Nov 2, 2021·8 cites·27 claims
- 0895US10267787B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Apr 23, 2019·13 cites·13 claims
- 0995US8999988B2Protein kinase inhibitorsUNIV ARIZONA STATE·Filed 2013·Granted Apr 7, 2015·17 cites·12 claims
- 1094US11578061B2Inhibitors of LRRK2 kinaseHALIA THERAPEUTICS INC·Filed 2022·Granted Feb 14, 2023·3 cites·27 claims
- 1194US10562925B2Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Feb 18, 2020·10 cites·20 claims
- 1294US10357488B2Predicting response to alvocidib by mitochondrial profilingTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Jul 23, 2019·12 cites·8 claims
- 1394US7998966B2Axl kinase inhibitorsSUPERGEN INC·Filed 2008·Granted Aug 16, 2011·30 cites·8 claims
- 1494US7335662B2Substituted tricyclic compounds as protein kinase inhibitorsUNIV ARIZONA·Filed 2005·Granted Feb 26, 2008·25 cites·10 claims
- 1594US7326713B2Substituted tricyclic compound as protein kinase inhibitorsUNIV ARIZONA·Filed 2005·Granted Feb 5, 2008·26 cites·10 claims
- 1694US7312226B2Substituted tricyclic compounds as protein kinase inhibitorsUNIV ARIZONA·Filed 2005·Granted Dec 25, 2007·26 cites·11 claims
- 1793US11866423B2Inhibitors of LRRK2 kinaseHALIA THERAPEUTICS INC·Filed 2022·Granted Jan 9, 2024·2 cites·26 claims
- 1893US10132797B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2017·Granted Nov 20, 2018·15 cites·15 claims
- 1993US9155629B2Ankle and foot bone growth compositions and methodsREMINGTON BENJAMIN J·Filed 2011·Granted Oct 13, 2015·17 cites·18 claims
- 2093US8901120B2Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinaseBEARSS DAVID J·Filed 2012·Granted Dec 2, 2014·17 cites·31 claims
- 2192US10624880B2Predicting response to alvocidib by mitochondrial profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Apr 21, 2020·7 cites·16 claims
- 2292US10422788B2Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Sep 24, 2019·11 cites·19 claims
- 2392US10202356B2JAK2 and ALK2 inhibitors and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2014·Granted Feb 12, 2019·12 cites·10 claims
- 2492US7939546B2Quinoline derivatives for modulating DNA methylationSUPERGEN INC·Filed 2009·Granted May 10, 2011·14 cites·17 claims
- 2592US7326712B2Substituted tricyclic compounds as protein kinase inhibitorsUNIV ARIZONA·Filed 2004·Granted Feb 5, 2008·39 cites·22 claims
- 2691US11713321B2Inhibitors of NEK7 kinaseHALIA THERAPEUTICS INC·Filed 2021·Granted Aug 1, 2023·2 cites·22 claims
- 2791US10682356B2Combination therapies for treatment of cancerTOLERO PHARMACEUTICALS INC·Filed 2019·Granted Jun 16, 2020·7 cites·1 claims
- 2890US11497756B2Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidibSUMITOMO PHARMA ONCOLOGY INC·Filed 2018·Granted Nov 15, 2022·4 cites·18 claims
- 2987US11793802B2Treatment of acute myeloid leukemia (AML) with venetoclax failureSUMITOMO PHARMA ONCOLOGY INC·Filed 2020·Granted Oct 24, 2023·8 cites·20 claims
- 3087US8703767B2Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitorsBEARSS DAVID J·Filed 2012·Granted Apr 22, 2014·10 cites·18 claims
- 3185US7790746B2Quinoline derivatives for modulating DNA methylationSUPERGEN INC·Filed 2007·Granted Sep 7, 2010·10 cites·16 claims
- 3284US9206176B2Substituted N-(3-(pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitorsUNIV UTAH RES FOUND·Filed 2014·Granted Dec 8, 2015·6 cites·18 claims
- 3383US12428404B2Inhibitors of LRRK2 kinaseHALIA THERAPEUTICS INC·Filed 2023·Granted Sep 30, 2025·0 cites·22 claims
- 3483US10752594B2JAK1 and ALK2 inhibitors and methods for their useTOLERO PHARMACEUTICALS INC·Filed 2018·Granted Aug 25, 2020·1 cites·11 claims
- 3583US8552018B2Substituted tricyclic compounds as protein kinase inhibitorsHURLEY LAURENCE H·Filed 2011·Granted Oct 8, 2013·7 cites·7 claims
- 3683US8088402B2Bone growth compositions and methodsREMINGTON BENJAMIN J·Filed 2006·Granted Jan 3, 2012·22 cites·25 claims
- 3781US8710057B2Imidazo[1,2-B]pyridazine and pyrazolo[1 .5-A]pyrimidine derivatives and their use as protein kinase inhibitorsBEARSS DAVID J·Filed 2011·Granted Apr 29, 2014·5 cites·16 claims
- 3881US7108862B2Bone growth compositions and methodsNEUROPRO TECHNOLOGIES INC·Filed 2003·Granted Sep 19, 2006·67 cites·57 claims
- 3979US2024083855A1Jak2 and alk2 inhibitors and methods for their useSUMITOMO PHARMA AMERICA INC·Filed 2023·Application pending·0 cites
- 4078US12091413B2Inhibitors of NEK7 kinaseHALIA THERAPEUTICS INC·Filed 2023·Granted Sep 17, 2024·0 cites·20 claims
- 4177US12338261B2Alvocidib prodrugs having increased bioavailabilitySUMITOMO PHARMA ONCOLOGY INC·Filed 2021·Granted Jun 24, 2025·0 cites·10 claims
- 4276US11040038B2Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the sameSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2019·Granted Jun 22, 2021·1 cites·11 claims
- 4376US7041309B2Spinal fusion using an HMG-CoA reductase inhibitorNEUROPRO TECHNOLOGIES INC·Filed 2002·Granted May 9, 2006·50 cites·26 claims
- 4475US8987335B2Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitorsVANKAYALAPATI HARIPRASAD·Filed 2012·Granted Mar 24, 2015·1 cites·8 claims
- 4574US2024075033A1Alk5 inhibitors for treating myelodysplastic syndromeSUMITOMO PHARMA ONCOLOGY INC·Filed 2023·Application pending·0 cites
- 4673US2020131210A1Alvocidib prodrugs having increased bioavailabilityTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4772US2020200737A1Profiling peptides and methods for sensitivity profilingTOLERO PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 4871US9828376B2Substituted N-(3-pyrimidin-4-yl)phenyl)acrylamide analogs as tyrosine receptor kinase BTK inhibitorsUNIV UTAH RES FOUND·Filed 2013·Granted Nov 28, 2017·1 cites·14 claims
- 4971US9266838B2Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitorsVANKAYALAPATI HARIPRASAD·Filed 2013·Granted Feb 23, 2016·1 cites·8 claims
- 5071US2021052568A1Predicting response to alvocidib by mitochondrial profilingSUMITOMO DAINIPPON PHARMA ONCOLOGY INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 106 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when David J. Bearss files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →